Inside the Singapore Randomized Trial
Two studies published within days of each other point in the same direction. When women who are due for cervical cancer screening are offered the option of collecting their own sample, more of them complete the screening.
The first, a pragmatic randomized controlled trial published in The Annals of Family Medicine, enrolled 650 women aged 30 to 69 in Singapore's public primary care system, randomized in equal numbers. Both groups were first offered clinician sampling. The intervention group was additionally offered a self-collection kit if they declined the clinician exam. The usual-care group was offered clinician sampling only.
Screening uptake reached 56.6 percent in the intervention group against 42.8 percent in usual care, according to the journal's summary of the findings. Detection of high-risk HPV was 3.1 percent versus 0.3 percent.
That detection gap is larger than the uptake gap, and the reason is instructive. Most of the additional high-risk HPV was found among women who had never been screened before. Seven of the 10 high-risk cases came from previously unscreened women, and five of those were picked up through self-sampling.
The authors, led by researchers at Singapore's National Healthcare Group, wrote that "offering self-sampling HPV DNA testing alongside clinician sampling significantly increased screening uptake." Singapore screens roughly 43 percent of eligible women annually against a national target of 70 percent.
Reaching Patients at an Opioid Treatment Clinic Rarely Screens
The second study, published in JAMA Network Open, moved the question into a setting that does not normally do cancer screening at all.
Researchers at the University of Washington offered HPV self-collection to women attending an outpatient opioid treatment program. Women with substance use disorder tend to avoid routine medical care, screen less often, and carry a higher risk of persistent HPV infection, which makes them a population where cervical cancer is more likely to be caught late.
Of 194 patients, 174 were eligible. Of those, 158, or 90.8 percent, agreed to self-collect, completing the test in the program's restroom. Among them, 128 tested negative. Seven tested positive for HPV-16 or HPV-18, the two types responsible for most cervical cancers, and 23 tested positive for another high-risk type.
The authors wrote that "using HPV self-collection testing was feasible and acceptable." That framing is precise, and so is the study's most important limitation: of the 30 patients with a positive result, only 16 went on to follow-up care. Roughly half did not.
A positive HPV test is not a diagnosis. It is a signal that requires colposcopy or repeat testing to act on. Screening that is not followed by follow-up does not prevent cancer, and CIDRAP's summary of both studies notes the same gap.
The U.S. Rules on Who Can Self-Collect and Where
Self-collection is a different way of taking the sample, not a different test. The specimen is a vaginal swab rather than a cervical one, and it is run on the same laboratory HPV platforms clinicians already use.
U.S. authorization arrived in two steps. In May 2024, FDA approved self-collection for use in a health care setting on the BD Onclarity and Roche cobas platforms, meaning a patient could collect the sample herself in a clinic room rather than undergo a speculum exam. In May 2025, the FDA approved the first at-home self-collection device, a prescription product paired with a telehealth service for people aged 25 to 65 at average risk.
The comparison with conventional cytology matters here. A Pap test examines cervical cells for abnormal changes. Primary HPV testing looks for the virus that causes nearly all cervical cancers, and it is more sensitive for identifying who is at risk. Self-collection is currently positioned within HPV primary screening, not as a replacement for cytology in the age groups where cytology is still the recommendation.
Federal guidance caught up in January. The Health Resources and Services Administration added self-collection to its Women's Preventive Services Guidelines and designated high-risk HPV testing, patient- or clinician-collected, as the preferred method for average-risk women aged 30 to 65. Cytology every three years remains the recommendation for ages 21 to 29. HRSA Administrator Tom Engels said the changes "represent a significant step forward in cervical cancer screening."
Evidence Limits Worth Naming
Neither study measured cervical cancer cases or deaths. Both measured process outcomes: uptake, detection, and in one case follow-up completion. That is a legitimate and useful endpoint, but it is not the same as demonstrating fewer cancers.
The Singapore trial was conducted in a public primary care system with a national screening program. Its uptake figures should not be read directly onto the fragmented U.S. system. The Washington study was a single-site feasibility and acceptability study without a randomized comparison group, so it cannot establish that self-collection increased screening relative to what would have happened otherwise.
Both are small by cancer-screening standards. The absolute number of high-risk HPV detections in the Singapore trial was 10.
What the studies do not resolve is the follow-up problem, and that is the crux. Earlier U.S. work has shown the same pattern, with strong uptake of self-collection paired with weaker completion of colposcopy afterward. Expanding the front door of screening without building the second step risks generating positive results that never reach treatment.
Coverage Changes Arriving in 2027
The financial picture shifts on a fixed date. Under the updated HRSA guidelines, most non-grandfathered private health plans must cover self-collected cervical cancer screening for average-risk women aged 30 to 65 without cost sharing, along with additional testing needed to complete the screening process, for plan years beginning on or after January 1, 2027.
Until then, coverage varies. At-home kits may carry out-of-pocket costs, and patients should confirm with their plan before ordering. In-clinic self-collection is generally billed as screening.
Women who are overdue can ask their primary care clinic directly whether in-clinic self-collection is available, since many practices now offer it without advertising it. Uninsured patients can check the CDC's National Breast and Cervical Cancer Early Detection Program and local federally qualified health centers, which provide screening on a sliding scale.
The confirmed finding is that offering a self-collection option raised screening completion in two different settings. The people most affected are women who have never been screened or are years overdue. The reasonable action is asking a clinic whether the option exists, not ordering a test and treating a negative result as permanent reassurance. The central uncertainty is whether follow-up care can keep pace with the additional positive results that wider screening will produce.
Frequently Asked Questions
What is HPV self-collection? The patient collects her own vaginal swab instead of undergoing a speculum exam. The sample is then run on the same laboratory HPV test a clinician-collected sample would use.
Is self-collection available in the United States? Yes. FDA approved self-collection in health care settings in 2024 and approved a prescription at-home device in 2025 for people aged 25 to 65 at average risk.
Does self-collection replace the Pap test? Not entirely. It is used within primary HPV screening. Federal guidance still recommends cervical cytology every three years for average-risk women aged 21 to 29.
What did the two new studies find? Both found higher screening completion when self-collection was offered. The Singapore trial reported 56.6 percent uptake versus 42.8 percent, and the Washington clinic study reported 90.8 percent uptake among eligible patients.
Does a positive HPV result mean cancer? No. It means a high-risk type was detected and follow-up testing is needed. Most HPV infections clear on their own.
Will insurance cover self-collection? Most private plans must cover it without cost sharing for average-risk women aged 30 to 65 for plan years beginning on or after January 1, 2027. Before then, check with your plan.
What if I am uninsured and overdue for screening? Federally qualified health centers and the CDC's National Breast and Cervical Cancer Early Detection Program offer low-cost or free screening in many areas.
